Advertisement

Clinical & Experimental Metastasis

, Volume 17, Issue 7, pp 555–566 | Cite as

Expression of matrix metalloproteinases and their inhibitors in human brain tumors

  • Zarin Kachra
  • Edith Beaulieu
  • Louis Delbecchi
  • Nathalie Mousseau
  • France Berthelet
  • Robert Moumdjian
  • Rolando Del Maestro
  • Richard Béliveau
Article

Abstract

Sixty human brain tumors, classified according to the New World Health Organization (WHO) classification including, grade I schwannomas, meningiomas and pilocytic astrocytomas, grade II astrocytomas, grade III anaplastic astrocytomas, grade IV glioblastomas, grade III anaplastic oligodendrogliomas and grade IV glioblastomas and lung and melanoma metastases were analyzed for the expression of three matrix metalloproteinases (MMPs), two tissue inhibitors of MMPs (TIMPs) and for MMP activity. Some correlation was found between MMP expression and the degree of malignancy. Western blotting analysis revealed a more uniform pattern of distribution of MMP-2 (gelatinase A) than of MMP-9 (gelatinase B) and MMP-12 (metalloelastase) among tumors. MMP-9 levels were found to be significantly higher in grade III anaplastic astrocytomas and anaplastic oligodendrogliomas than those in grade I schwannomas and meningiomas. Anaplastic astrocytomas and Grade IV glioblastomas expressed significantly higher levels MMP-12 than grade I meningiomas. All sixty tumors showed a similar pattern of activity in zymography, proMMP-9 being the major species detected. Interestingly, TIMP-1 and TIMP-2 expression levels were especially low in tumors of grade II and grade III but significantly higher in tumors of grade I, particularly in schwannomas. Taken together, these data suggest that: 1) a balance between MMPs and TIMPs has an important role to play in human brain tumors; 2) TIMP expression may be valuable markers for tumor malignancy.

matrix metalloproteinase tumor angiogenesis tumor invasion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T et al. Microvessel density in brain tumors. Anticancer Res 1997; 17: 4747–54.PubMedGoogle Scholar
  2. 2.
    Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996; 49: 117–37.PubMedGoogle Scholar
  3. 3.
    Stetler-Stevenson WG, Corcoran ML. Tumor angiogenesis: Functional similarities with tumor invasion. In Goldberg ID and Rosen EM (ed): Regulation of Angiogenesis. Basel, Switzerland: Birkhaüser 1997; 413–8.Google Scholar
  4. 4.
    Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993; 7: 1434–41.PubMedGoogle Scholar
  5. 5.
    Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062–72.PubMedGoogle Scholar
  6. 6.
    Powell WC, Matrisian LM. Complex roles of matrix metalloproteinases intumor progression. Curr Top Microbiol Immunol 1996; 213: 1–21.PubMedGoogle Scholar
  7. 7.
    Mohanam S, Wang SW, Rayford A et al. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis 1995; 13: 57–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Nuovo GJ, MacConnell PB, Simsir A et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 267–75.PubMedGoogle Scholar
  9. 9.
    Sugiura Y, Shimada H, Seeger RC et al. Matrix metalloproteinases-2 and-9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998; 58: 2209–16.PubMedGoogle Scholar
  10. 10.
    Reynolds JJ. Collagenases and tissue inhibitors of metalloproteinases: A functional balance in tissue degradation. Oral Dis 1996; 2: 70–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Pei D. Identification and characterization of the fifth membrane-type matrixmetalloproteinase MT5-MMP. J Biol Chem 1999; 274: 8925–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Bartlett JD, Simmer JP, Xue J et al. Molecular cloning and mRNA tissue distribution of a novel matrix metalloproteinase isolated from porcine enamel organ. Gene 1996; 183: 123–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Cossins J, Dudgeon TJ, Catlin G et al. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem Biophys Res Commun 1996; 228: 494–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Stolow MA, Bauzon DD, Li J et al. dentification and characterization of a novel collagenase in Xenopus laevis: Possible roles during frog development. Mol Biol Cell 1996; 7: 1471–83.PubMedGoogle Scholar
  15. 15.
    Llano E, Pendas AM, Knäuper V et al. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 1997; 36: 15101–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Pendas AM, Knäuper V, Puente XS et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang M, Murray MT, Kurkinen M. A novel matrix metalloproteinase gene (XMMP) encoding vitronectin-like motifs is transiently expressed in Xenopus laevis early embryo development. J Biol Chem 1997; 272: 13527–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG. MMP-2: Expression, activation and inhibition. Enzyme Protein 1996; 49: 7–19.PubMedGoogle Scholar
  19. 19.
    Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-site zinc complex in latency and a ‘cysteine switch’ mechanism for activation. Proc Natl Acad Sci USA 1990; 87: 364–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Greene J, Wang M, Liu YE et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Goldberg GI, Strongin A, Collier IE et al. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 4583–91.PubMedGoogle Scholar
  22. 22.
    Strongin AY, Collier I, Bannikov G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Khokha R, Zimmer MJ, Wilson SM, Chambers AF. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 1992; 10: 365–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Johnson MD, Kim HR, Chesler L et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160: 194–202.PubMedCrossRefGoogle Scholar
  26. 26.
    Imren S, Kohn DB, Shimada H et al. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891–5.PubMedGoogle Scholar
  27. 27.
    Watanabe M, Takahashi Y, Ohta T et al. Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 1996; 77: 1676–80.PubMedGoogle Scholar
  28. 28.
    Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107: 2373–9.PubMedGoogle Scholar
  29. 29.
    Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995; 270: 13453–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Sato H, Takino T, Okada Y, Cao J et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Imai K, Ohuchi E, Aoki T et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res 1996; 56: 2707–10.PubMedGoogle Scholar
  32. 32.
    Butler GS, Butler MJ, Atkinson SJ et al. The TIMP2 membrane type 1 metalloproteinase ‘receptor’ regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 1998; 273: 871–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Rooprai HK, McCormick D. Proteases and their inhibitors in human brain tumors: A review. Anticancer Res 1997; 17: 4151–62.PubMedGoogle Scholar
  34. 34.
    Nakagawa T, Kubota T, Kabuto M et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994; 81: 69–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Rooprai HK, Van Meter T, Rucklidge GJ et al. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours. Int J Oncol 1998; 13: 1153–7.PubMedGoogle Scholar
  36. 36.
    Rao JS, Steck PA, Mohanam S et al. Elevated levels of M(r) 92000 type IV collagenase in human brain tumors. Cancer Res 1993; 53: 2208–11.PubMedGoogle Scholar
  37. 37.
    Zülch KJ. Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology 1980; 19: 59–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548–55.PubMedGoogle Scholar
  40. 40.
    Colton CA, Keri JE, Chen WT, Monsky WL. Protease production by cultured microglia: Substrate gel analysis and immobilized matrix degradation. J Neurosci Res 1993; 35: 297–304.PubMedCrossRefGoogle Scholar
  41. 41.
    Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: Detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Matsumoto S, Koayashi T, Katoh M et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: Relationship to lesion development. Am J Pathol 1998; 153: 109–19.PubMedGoogle Scholar
  43. 43.
    Curci JA, Lio S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrixmetalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998; 102: 1900–10.PubMedCrossRefGoogle Scholar
  44. 44.
    Wagner S, Stegen C, Bouterfa H et al. Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. J Neurooncol 1998; 40: 113–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Forsyth PA, Wong H, Laing TD et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999; 79: 1828–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Lampert K, Machein U, Machein MR et al. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Path 1998; 153: 429–39.PubMedGoogle Scholar
  47. 47.
    Del Maestro RF. Angiogenesis. InBerger M, Wilson C (eds): The Gliomas. Philadelphia, Pennsylvania: W.B. Saunders, 1998; 87–106.Google Scholar
  48. 48.
    Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999; 84: 10–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Plat KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995; 15: 339-47.CrossRefGoogle Scholar
  50. 50.
    Zhang H, Kelly G, Zerrilo C et al. Expression of a cleaved Brainspecific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci 1998; 18: 2370–6.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Zarin Kachra
    • 1
  • Edith Beaulieu
    • 1
  • Louis Delbecchi
    • 1
  • Nathalie Mousseau
    • 1
  • France Berthelet
    • 2
  • Robert Moumdjian
    • 1
  • Rolando Del Maestro
    • 3
  • Richard Béliveau
    • 1
  1. 1.Laboratoire de médecine moléculaire, Centre de cancérologie Charles-BruneauHôpital Ste-Justine-UQAMCanada
  2. 2.Hôpital Notre-DameMontréal, Québec
  3. 3.Brain Research LaboratoriesLondon Health Sciences CentreLondonCanada

Personalised recommendations